[CONSOLIDATION_METHOD_TITLE] [CONSOLIDATION_METHOD]
Related Companies
[]
Related Funds
[]
English
oda_NewBusinessRelationAbstract|
New Business Relation
oda_UpdateAnnouncementFlag|
Update Notification Flag
Evet (Yes)
oda_CorrectionAnnouncementFlag|
Correction Notification Flag
Hayır (No)
oda_DateOfThePreviousNotificationAboutTheSameSubject|
Date Of The Previous Notification About The Same Subject
16.11.2021
oda_DelayedAnnouncementFlag|
Postponed Notification Flag
Hayır (No)
oda_AnnouncementContentSection|
Announcement Content
oda_NatureOfTheOtherPartyWithWhichNewBusinessRelationWillStart|
Nature Of The Other Party With Which New Business Relation Will Start
Tedarikçi (Supplier)
oda_NameSurnameOrCompanyTitleOfCustomerOrSupplier|
Name Surname Or Company Title Of Customer Or Supplier
Sanovel İlaç Sanayi ve Ticaret A.Ş.
oda_IfExistsShareOfCustomerOrSupplierInNetSalesOrCostOfGoodsSoldOnLatestDisclosedProfitOrLossAndOtherComprehensiveIncomeStatementOfCompany|
If Exists Share Of Customer Or Supplier In Net Sales Or Cost Of Goods Sold On Latest Disclosed Profit Or Loss And Other Comprehensive Income Statement Of Company
-
oda_IfExistsShareOfCustomerOrSupplierInTradeReceivablesOrDebtsOnLatestDisclosedStatementofFinancialPositionOfCompany|
If Exists Share Of Customer Or Supplier In Trade Receivables Or Debts On Latest Disclosed Statement of Financial Position Of Company
-
oda_ExpectedStartingDateOfNewBusinessRelation|
Expected Starting Date O fNew Business Relation
06/09/2022
oda_IfExistSignificantProvisionsOfTheContractTextBlock|
If Exist Significant Provisions Of The Contract
Detailed below
oda_ImpactOfNewBusinessRelationOnCompanyActivities|
Impact Of New Business Relation On Company Activities
It will have positive impact on Company's activities on a global basis.
oda_ExplanationSection|
Explanations
oda_ExplanationTextBlock|

-Unofficial Translation-

Scope of the Products stated to be sold and distributed in Azerbaijan and Uzbekistan in the Material Event Disclosure titled as "Signing Agreement with Sanovel İlaç Sanayi ve Ticaret A.Ş." made on 16.11.2021 ( https://www.kap.org.tr/en/Bildirim/978109 ) has changed.

With the additional protocol signed between parties on 08.09.2022, scope of products has been re-determined as Ticagrelor which used for treatment of acute coronary diseases, Nebivalol which used for treatment of hypertension and heart failure and Levetıracetam which used for treatment of epilepsy.

In this context, the contribution of the drugs under the contract stipulated in the previous announcement to the sales of our company has also changed. In the last situation, expected contribution of the said Agreement to our Company's sales is 8000 boxes and approximately USD 71,000.00 (TL 1,290,000.00) for 2022, 87000 boxes and approximately USD 435,000.00 (TL 7,910,000.00) for 2023 and 138800 boxes and approximately USD 656,000.00 (TL 11,930,000.00) for 2024.